U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Uveal Melanoma

MedGen UID:
1726417
•Concept ID:
C5419539
•
Neoplastic Process

Definition

Uveal melanoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Uveal Melanoma

Professional guidelines

PubMed

Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J
J Clin Oncol 2023 Oct 20;41(30):4794-4820. Epub 2023 Aug 14 doi: 10.1200/JCO.23.01136. PMID: 37579248
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z, Xie Y, Wang JQ, Cheng Y, Fleishman J, Chen ZS, Chen Y
Drugs Today (Barc) 2023 Mar;59(3):179-193. doi: 10.1358/dot.2023.59.3.3542417. PMID: 36847626
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN, Carvajal RD
Expert Rev Anticancer Ther 2022 Oct;22(10):1017-1027. Epub 2022 Sep 19 doi: 10.1080/14737140.2022.2124971. PMID: 36102132Free PMC Article

Recent clinical studies

Therapy

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P
N Engl J Med 2023 Dec 14;389(24):2256-2266. Epub 2023 Oct 21 doi: 10.1056/NEJMoa2304753. PMID: 37870955Free PMC Article
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J
J Clin Oncol 2023 Oct 20;41(30):4794-4820. Epub 2023 Aug 14 doi: 10.1200/JCO.23.01136. PMID: 37579248
T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ, Zweegman S
Lancet 2023 Jul 8;402(10396):142-158. Epub 2023 Jun 1 doi: 10.1016/S0140-6736(23)00521-4. PMID: 37271153
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN, Carvajal RD
Expert Rev Anticancer Ther 2022 Oct;22(10):1017-1027. Epub 2022 Sep 19 doi: 10.1080/14737140.2022.2124971. PMID: 36102132Free PMC Article
Tebentafusp: First Approval.
Dhillon S
Drugs 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4. PMID: 35364798

Prognosis

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH
Ann Surg Oncol 2024 Aug;31(8):5340-5351. Epub 2024 May 4 doi: 10.1245/s10434-024-15293-x. PMID: 38704501Free PMC Article
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M
J Clin Oncol 2023 Aug 10;41(23):3917-3929. Epub 2023 Jun 12 doi: 10.1200/JCO.22.02199. PMID: 37307514
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z, Xie Y, Wang JQ, Cheng Y, Fleishman J, Chen ZS, Chen Y
Drugs Today (Barc) 2023 Mar;59(3):179-193. doi: 10.1358/dot.2023.59.3.3542417. PMID: 36847626
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN, Carvajal RD
Expert Rev Anticancer Ther 2022 Oct;22(10):1017-1027. Epub 2022 Sep 19 doi: 10.1080/14737140.2022.2124971. PMID: 36102132Free PMC Article
Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.
Zhuo H, Zhou L
Pharmazie 2016 Oct 1;71(10):555-561. doi: 10.1691/ph.2016.6683. PMID: 29441921

Clinical prediction guides

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH
Ann Surg Oncol 2024 Aug;31(8):5340-5351. Epub 2024 May 4 doi: 10.1245/s10434-024-15293-x. PMID: 38704501Free PMC Article
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P
N Engl J Med 2023 Dec 14;389(24):2256-2266. Epub 2023 Oct 21 doi: 10.1056/NEJMoa2304753. PMID: 37870955Free PMC Article
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M
J Clin Oncol 2023 Aug 10;41(23):3917-3929. Epub 2023 Jun 12 doi: 10.1200/JCO.22.02199. PMID: 37307514
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML, Samim M, Kapiteijn E, Meijer TS, Speetjens FM, Brüning R, Schroeder TH, El-Sanosy S, Maschke H, Wacker FK, Vogel A, Dewald CLA, Goeman JJ, Burgmans MC
Cardiovasc Intervent Radiol 2022 Sep;45(9):1304-1313. Epub 2022 Aug 3 doi: 10.1007/s00270-022-03225-9. PMID: 35922562Free PMC Article
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV, Steeb T, Schlager JG, Rosumeck S, Dressler C, Ruzicka T, Nast A, Berking C
Cancer Treat Rev 2017 Nov;60:44-52. Epub 2017 Aug 24 doi: 10.1016/j.ctrv.2017.08.009. PMID: 28881222

Recent systematic reviews

Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J
J Clin Oncol 2023 Oct 20;41(30):4794-4820. Epub 2023 Aug 14 doi: 10.1200/JCO.23.01136. PMID: 37579248
Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review.
Alexander H, Wen D, Chu M, Han C, Hadden P, Thomas R, Bartlett A
Br J Radiol 2022 Jan 1;95(1129):20210200. Epub 2021 Nov 10 doi: 10.1259/bjr.20210200. PMID: 34757824Free PMC Article
Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P
J Clin Oncol 2020 Nov 20;38(33):3947-3970. Epub 2020 Mar 31 doi: 10.1200/JCO.20.00198. PMID: 32228358
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C
Eur J Cancer 2018 Nov;103:41-51. Epub 2018 Sep 8 doi: 10.1016/j.ejca.2018.08.005. PMID: 30205280
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV, Steeb T, Schlager JG, Rosumeck S, Dressler C, Ruzicka T, Nast A, Berking C
Cancer Treat Rev 2017 Nov;60:44-52. Epub 2017 Aug 24 doi: 10.1016/j.ctrv.2017.08.009. PMID: 28881222

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...